Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7211
+0.0146 (2.07%)
At close: May 21, 2026, 4:00 PM EDT
0.7305
+0.0094 (1.30%)
After-hours: May 21, 2026, 7:42 PM EDT
Longeveron Employees
Longeveron had 38 employees as of December 31, 2025. The number of employees increased by 12 or 46.15% compared to the previous year.
Employees
38
Change (1Y)
12
Growth (1Y)
46.15%
Revenue / Employee
$32,000
Profits / Employee
-$590,237
Market Cap
21.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 38 | 12 | 46.15% | 38 | 0 |
| Dec 31, 2024 | 26 | 2 | 8.33% | 26 | 0 |
| Dec 31, 2023 | 24 | 3 | 14.29% | 23 | 1 |
| Dec 31, 2022 | 21 | 1 | 5.00% | 19 | 2 |
| Dec 31, 2021 | 20 | 8 | 66.67% | 18 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Werewolf Therapeutics | 39 |
| Quince Therapeutics | 38 |
| Curis | 24 |
| BriaCell Therapeutics | 16 |
| Sensei Biotherapeutics | 15 |
| Lipocine | 14 |
| Cellectar Biosciences | 11 |
| VYNE Therapeutics | 10 |
LGVN News
- 1 day ago - Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities - GlobeNewsWire
- 1 day ago - Longeveron Proxy statement: Proxy filing - Filings
- 1 day ago - Longeveron Proxy statement: Proxy filing - Filings
- 8 days ago - Longeveron reports Q1 EPS (19c) vs. (34c) last year - TheFly
- 8 days ago - Longeveron Earnings Call Transcript: Q1 2026 - Transcripts
- 8 days ago - Longeveron Quarterly report: Q1 2026 - Filings
- 8 days ago - Longeveron Earnings release: Q1 2026 - Filings
- 8 days ago - Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update - GlobeNewsWire